WT
TVTX icon

Whittier Trust’s Travere Therapeutics TVTX Stock Holding History

Whittier Trust’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$394 – 1426
2025
Q3 		$394 Buy
+16
New +$301 ﹤0.01% 1359

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Whittier Trust's TVTX Position: Q4 2025 in Review

Whittier Trust sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 16 shares — an estimated $394 sold.

Whittier Trust first reported a position in TVTX in Q3 2025 and held it in 1 quarter. The position peaked at $394 in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Whittier Trust reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Whittier Trust sold 16 Travere Therapeutics shares in Q4 2025, an estimated $394.
  • Whittier Trust first reported a position in Travere Therapeutics in Q3 2025 and held it in 1 quarter.
  • Whittier Trust's Travere Therapeutics position peaked at $394 in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Whittier Trust's 13F filing for Q4 2025, filed 26 Jan 2026.